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Abstract: A previous proteomic screen in our laboratory identified nuclear factor 45 (NF45) and
nuclear factor 90 (NF90) as potential cellular factors involved in human immunodeficiency virus
type 1 (HIV-1) replication. Both are RNA binding proteins that regulate gene expression; and
NF90 has been shown to regulate the expression of cyclin T1 which is required for Tat-dependent
trans-activation of viral gene expression. In this study the roles of NF45 and NF90 in HIV replication
were investigated through overexpression studies. Ectopic expression of either factor potentiated HIV
infection, gene expression, and virus production. Deletion of the RNA binding domains of NF45 and
NF90 diminished the enhancement of HIV infection and gene expression. Both proteins were found
to interact with the HIV RNA. RNA decay assays demonstrated that NF90, but not NF45, increased
the half-life of the HIV RNA. Overall, these studies indicate that both NF45 and NF90 potentiate HIV
infection through their RNA binding domains.
Keywords: HIV; NF45; NF90; transcription; RNA regulation
1. Introduction
Like all viruses, human immunodeficiency virus (HIV) requires host cell factors for productive
replication. HIV produces only 15 proteins but replicates in several cell lineages and exhibits a complex
life cycle [1]. In addition, the host cell elicits an innate response to defend against viral infection
and spread. Characterization of both the pro- and anti-viral factors during infection may discover
new targets for the development of novel therapeutic strategies that inhibit virus replication and/or
pathogenesis. A number of genetic and proteomic studies have been undertaken to identify cellular
factors involved in HIV replication and the current National Institutes of Health (NIH) interaction
database contains greater than 3000 proteins [2]. Given the size of the database, it is disappointing that
only one antiviral compound targeting a cell factor, Maroviroc, has been approved for clinical use as
an anti-viral inhibitor [3].
Our laboratory has completed a number of proteomic screens for HIV factors [4–6]. Nuclear factor
45 and nuclear factor 90 (NF45 and NF90, respectively) were identified as candidate HIV factors in a
screen of HIV nucleoprotein complexes [5]. These proteins are the products of the interleukin enhancer
binding factor 2 and 3 genes (ILF2 and 3, respectively). Both proteins participate extensively in RNA
metabolism, including the regulation of messenger, noncoding, and regulatory RNAs. NF45 and
NF90 are distinct proteins, but share common domains (Figure 1). NF45 has an N-terminal arginine-
and glycine rich (RGG) domain at position 3–22, and a domain associated with zinc fingers (DZF) at
position 104–338. NF90 has an N-terminal DZF and C-terminal RGG domain. It also has a defined
nuclear localization signal as well as two double stranded RNA binding (DRBM) motifs. In addition
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to their individual functions, NF45 and NF90 can heterodimerize via their DZF domains to form a
RNA regulatory complex. The NF45-NF90 complex has been shown to interact with DNA-dependent
protein kinases (DNA-PK) and be involved in protein kinase C mediated DNA damage repair [7].
Both proteins also bind the interleukin (IL)-13 promoter HS-4 region and increase IL-13 expression
during T cell activation [8]. Recently, NF45 and NF90 are found to be the components of precursors
to 60S (pre-60S) ribosomal subunits [9]. NF45 has been shown to regulate the activity of NF90, and
the knockdown of NF90 destabilizes NF45 expression [9,10]. Alternative splicing of NF90 produces a
larger isoform, NF110, which contains an altered C-terminus with a distinct GQSR motif (Figure 1).
The C-terminal domain of NF110 has been shown to enhance Survivin expression [11], but overall the
functions of NF110 are less well understood. Similar to NF90 it binds RNA and can enhance gene
expression, although it appears to be bound to chromatin in the cell [12,13].
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Efficient HIV gene expression requires hyperphosphorylation of RNA polymerase II by the
Positive Transcription Elongation Factor b (P-TEFb), a complex of CDK9 and cyclin T1 [14–17].
Recruitment of P-TEFb is accomplished by the HIV regulatory protein Tat, which binds the small
step-loop trans-activation response element region (TAR) in the 51 end of the new synthesized viral
RNA. NF90 has been identified as a regulator of HIV transcription by modulating cyclin T1 expression.
Cyclin T1 expression requires binding of NF90 to the 31 UTR of its mRNA. Therefore, knockdown
of NF90 decreases HIV gene expression by reducing cyclin T1 levels [18]. Overexpression of NF90
can increase HIV promoter activity when co-transfected with an HIV reporter virus [13,18]. Other
studies have investigated the role of a C-terminal mutant of NF90 (NF90ctv). Expression of this mutant
disrupts Tat-dependent transcription by competitive binding of the TAR element [19]. It also interacts
with HIV Rev and inhibits its RNA export activity [20]. Although a later study demonstrated that
NF90ctv facilitated the export of gag mRNA in a Rev-independent manner [21]. However, the NF90ctv
isoform is not expressed in cells and may not be biologically relevant [18,22].
Combined, previous studies show that NF90 is required for HIV gene expression by regulating
cyclin T1 expression. In this study, we further investigated the roles of NF45 and NF90 in HIV
replication using overexpression studies. Our results show that both proteins promote HIV infection.
The RNA binding domains were required for the effect as deletion of RGG domain in NF45 or deletion
of DRBMs in NF90 reduced any potentiation. Notably, the overexpression of either protein did not
affect Cyclin T1 levels in cells. NF45 and NF90 were also found to bind HIV RNA in vitro, although the
interactions appear to be sequence independent. Finally, RNA stability assays demonstrated that NF90
increased the half-life of HIV RNA, suggesting a second mechanism for the enhancement of HIV gene
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expression. Combined with previous studies, these results show NF45 and NF90 can potentiate HIV
infection and define additional mechanisms by which NF45 and NF90 modulate HIV gene expression.
2. Materials and Methods
2.1. Cell Culture
293T and HeLa Tet-On® 3G cells (Clontech Laboratories, Mountain View, CA, USA) were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% Fetal Clone III (Hyclone,
Logan, UT, USA), 100 U/mL penicillin and 100 µg/mL streptomycin. The media for the HeLa Tet-On®
3G also contained 100 µg/mL G418. All cells were grown at 37 ˝C with 5% CO2 in humidified incubator.
2.2. Proviral Clones and Expression Plasmids
The following plasmids have been described previously: pNLX [23], pNL4-3-Luc [24,25],
pSV2tat72 [26] and pBlue31LTR-Luc [27,28]. pCMV-NF45 was purchased from OriGene (OriGene,
Rockville, MD, USA). pEF6-NF90 was constructed by subcloning the NF90 ORF from pCMV-Sport6
(Thermo Fisher Scientific Inc., Waltham, MA, USA) into pEF6-TOPO by TOPO cloning
(Life Technologies, Carlsbad, CA, USA) using primers 51-ATGCGTCCAATGCGAATTTTTGTGAA
TG-31 and 51-CTAGGAAGACCCAAAATCATGATAG-31. pTarget-NF45 ∆RGG was constructed by
amplifying a truncated version of NF45 with the RGG region deleted and an artificial start codon
(underlined) inserted (primers: 51-ACCATGTTCAGGCCCTTTG-31 and 51-CTAGGAAGACCCAAAA
TCATGATAG-31). The amplicon was TA cloned into pTarget (Promega, Madison, WI, USA).
pTarget-NF90 ∆CT was similarly subcloned from pEF6-NF90 using 51-ATGCGTCCAATGCGAATTTTT
GTGAATG-31 and a 31 primer with a premature stop codon (underlined; 51-TTACCCGTCCTC
CTCCATTGGGCGTTT-31). The deletion mutant, pTarget-NF90 ∆DRBM, was constructed by PCR
overlap mutagenesis using the overlapping primers 51-GGGCGAGAGGGGTGTCTGCCTTCTC
CTCTTTCT-31 and 51-AGAAAGAGGAGAAGGCAGACACCCCTCTCGCCC-31.
pET28a(+)-NF45 and NF90 were generated by inserting NF45 and NF90 cDNA fragments into
pET28a EcoRI and NotI sites. pTRE-LTR was made by subcloning HIV LTR and R3 region using
primers 51-CGGGATCCTTTTGCCTGTACTGGG-31 and 51-CGACGCGTTGCTAGAGATTTTCCACA-31.
pGEM-T-IL2 was cloned from 293T cell RNA using standard cloning techniques (primers:
51-GCCTTCTATTTATTTAAATAT-31 and 51-TTATCAAATTTATTAAATAGTT-31). All the plasmids
used in this study were verified by sequencing using the Creighton University biomedical core facility
sequencing service.
2.3. Viral Assays
Viruses were prepared and normalized for infectivity as described previously [4,29]. For HIV
infection assays, 293T cells (~5 ˆ 104) were seeded in 24 well plates one day prior to transfection.
For overexpression experiment, cells were transfected with total 0.4 µg expression constructs or
control pcDNA3.1 0.4 µg vector using 1 mg/mL polyethylenimine (PEI). For knockdown experiment,
cells were transfected with small interfering RNAs (siRNAs) targets to NF45 and NF90 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at 1 ng/well in 6-well plates using Genmute reagent as directed
by the manufacturer (SignaGen, Gaithersburg, MD, USA). At 24 h post-transfection cells were infected
with virus for 4 h and the media changed. At 48 hours post-infection (hpi) the cells were lysed
with M-PER (Mammalian Protein Extraction Reagent; Thermo Fisher Scientific). The lysates were
cleared by centrifugation at 10,000ˆ g for 4 min at 4 ˝C and luciferase (Luc) activity measured
using ONE-Glo™ Luciferase reagent and a GloMax®-96 Microplate Luminometer as directed by
the manufacturer (Promega). The luminometer reading (RLU) for each sample was normalized to
its total protein concentration. To measure virus release from transduced cells, 1 ˆ 105 293T cells
were seeded in 6-well plates one day prior to transfection with 0.5 µg pCMV-NF45 or pEF6-NF90.
At 24 h post-transfection cells were infected with HIV pseudotyped with the vesicular stomatitis virus
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glycoprotein (VSVg) envelope for 4 h and the media changed. For the measurement of virus release
from cells co-transfected with the factors, cells were transfected with 0.5 µg pCMV-NF45, pEF6-NF90
plus 0.1 µg pNLX overnight followed by a media change. Cell supernatants were collected at 8 h post
media change in both experiments. Virus release was measured by in vitro reverse transcription assays
as previously described [30]. For virus expression assays each culture was transfected with expression
construct and control vector pCDNA3.1 0.4 µg plus 0.1 µg pNL4-3-Luc. At 48 h post-transfection,
cells were lysed and analyzed for Luc activity. MTT assays were performed using the CellTiter 96
non-radioactive cell proliferation assay according to the manufacturer’s instructions (Promega).
2.4. Immunobloting
Cell samples were lysed and mixed 1:1 with 2ˆ sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) loading buffer, boiled for 10 min and separated by SDS-PAGE. Proteins
were transferred to polyvinylidene fluoride (PVDF) and detected by Western blot using the following
primary antibodies: anti-NF45 (A-8), anti-actin (I-19) and anti-cyclin T1 (T-18) were all obtained from
Santa Cruz Biotechnology; anti-FLAG (M2) was from Sigma (St. Louis, MO, USA) and the anti-NF90
antibody was from Abgent (San Diego, CA, USA). Primary antibody incubations were 1 h, except
the detection of the NF90 deletion mutants with the Abgent antibody required an increased length of
incubation (>3 h). Incubation (30 min) with HRP conjugated anti-rabbit, anti-mouse IgG secondary
(GE Healthcare, Piscataway, NJ, USA) or anti-goat IgG secondary (Sigma) antibody was used to detect
primary antibody binding, which was visualized by chemiluminescent staining (Pierce Biotechnology,
Waltham, MA, USA). Images were captured using radiographic film, scanned to computer, adjusted
for brightness and contrast if necessary, and cropped for size.
2.5. Immunoprecipitation-RT-PCR Assays
Immunoprecipitation-RT-PCR (IP-RT-PCR) assays were performed essentially as described
previously [31]. The cells were transfected 24 h prior to infection. At 24 hpi cells were washed
and lysed with RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton x-100, 1% Sodium
deoxycholate, 0.2% SDS and 1 mM EDTA). Cell lysates were precleared with agarose beads, then
incubated with anti-FLAG M2 magnetic beads (Sigma-Aldrich, St. Louis, MO, USA) for 12 h at
4 ˝C with rotation. Beads were washed 4 times with RIPA buffer and split into two tubes—one for
immunoblots and one for RNA isolation. The samples for RNA were treated with proteinase K for
30 min at 37 ˝C and RNA isolated by acid phenol-chloroform extraction. RNA was reverse transcribed
using MLV RNA reverse transcriptase, and DNA quantified by real-time PCR with gag-specific primers
(51-GAAGCGCGCACGGCAAGAGGC-31 and 51-GCACACAATAGAGGACTGCTATTGTA-31), using
iTaq Universal SYBR Green Supermix and a Bio-Rad CFX Connect Real-Time PCR detection system.
2.6. Purification of Recombination NF45 and NF90 Proteins and RNA Cross-Linking Assays
Recombinant NF45 and NF90 proteins (rNF45 and rNF90) were expressed in BL21 Escherichia coli
(E. coli) cells (Novagen, Madison, WI, USA). Harvested cells were lysed by EmulsiFlex-C3 (AVESTIN,
Ottawa, ON, USA), and His-tagged fusion proteins were purified under native conditions using
HisPur Cobalt Resin (Thermo Fisher Scientific) following the manufacturer’s protocol. The purity
of fusion proteins was confirmed by SDS-PAGE followed by Coomassie staining. Purified rNF45
and rNF90 proteins were dialyzed and stored in 50 mM Tris-HCl (pH 8.0), 50 mM NaCl and 10%
Glycerol at ´80 ˝C. The DNA templates for RNA probe production contained the T7 primer sequence
linked to the HIV target sequences. These were synthesized by PCR using a pNLX template or
pGEMT-IL2 template. Primers were as follows: U3 part 1 (sense 51-TAATACGACTCACTATA
GGGTGGAAGGGCTAATTTGG-31 and antisense 51-ATGCTGGCTCATAGGGTGTAACAAG-31) , U3
part 2 (sense 51-TAATACGACTCACTATAGGGGCTTGTTACACCCTATG-31 and antisense 51-CCAG
TACAGGCAAAAAGCAGCTGC-31), R (sense 51-TAATACGACTCACTATAGGGGGTCTCTGGTTAG
A-31 and antisense 51-TGAGCACTCAAGGCAAGCTTTATTG-31), U5 (sense 51-TAATACGACTTC
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ACTATAGGGAAGTAGTGTGTGCCCCG-31 and antisense 51-CTGCTAGAGTTTTCCACACTGACT-31)
and IL-2 31mRNA (sense 51-TAATACGACTCACTATAGGGGCCTTCTATTTATTAAATAT and antisense
51-TTATCAAATTTATTAAATAGTT-31).
RNA was generated by in vitro T7 transcription (New England Biolabs, Ipswich, MA, USA) in the
presence of [α-32P]UTP. Transcribed radiolabeled RNA was purified with a RNA probe purification kit
(Omega Bio-Tek, Norcross, GA, USA), denatured at 80 ˝C for 10 min in 20 mM Tris-HCl, pH 7.5, 100 mM
NaCl, annealed by slow cooling, and stored at –80 ˝C. For RNA-binding reactions, 2 µg purified GST,
rNF45 or rNF90 protein was incubated with probes in binding buffer (100 mM KCl, 1 mM MgCl2,
0.5 mM EDTA, 1 mM dithiothreitol, 50 g/mL yeast tRNA, and 10% glycerol) for 30 min at 37 ˝C.
A probe alone group was used as a negative control. After incubation, reaction samples were irradiated
with 4 ˆ 105 J using UV Stratalinker 1800 (Stratagene, La Jolla, CA, USA). Samples were treated with
0.1 mg/mL RNase A at 37 ˝C for 30 min, the reaction terminated by boiling 5 min in an equal volume
of 2ˆ sample buffer, and separated by 12% SDS-PAGE. Gels were dried, exposed to phosphorimager
screens overnight and imaged using a Typhoon 9400 phosphorimager (GE Healthcare).
2.7. RNA Decay Assays
The transfection and selection of the pTRE-LTR HeLa Tet-On® 3G Cell Line (HeLa-iLTR) was
performed following the manufacturer’s instructions (Clontech). For RNA decay assays, 1 ˆ 105
HeLa-iLTR cells were seeded into 6-well plates 24 h prior to transfection with 1 µg pCDNA3.1,
pCMV-NF45 or pEF6-NF90 using GenJet™ transfection reagent (SignaGen Laboratories, Rockville, MD,
USA) following the manufacturer’s instructions. At 24 h post transfection 10 ng/mL of doxycycline
was added to induce expression of HIV RNA. After 12 h of induction, the cells were washed
3 times and returned to cDMEM. Total RNA was harvested at 0, 8, 16, 24 and 32 h (Omega Biotech,
Norcross, GA, USA). RNA was reverse transcribed using random primers and cDNA was amplified
using primers (51-TCTGGCTAACTAGGGAACCCAC-3” and 51-CTGACTAAAAGGGTCTGAGG-31).
Primers designed to 18S RNA were used as an internal control (51-GTAACCCGTTGAACCCCATT-31
and 51-CCATCCAATCGGTAGTAGCG-31).
3. Results
3.1. The Overexpression of NF45 or NF90 Increases HIV Infection and Virus Production
In a previous proteomic study of HIV reverse transcription and preintegration complexes we
observed changes in the expression of NF45 and NF90 in HIV infected cells by mass spectrometry [5].
Since both NF45 and NF90 are RNA binding proteins, we speculated that they might participate in
the early steps of the HIV life cycle. Our initial approach was to examine the effect of over-expressing
each protein on HIV infection. Cells were transfected with individual expression constructs 24 h
prior to transduction with a HIV luciferase reporter virus (HIV-Luc) pseudotyped with the VSVg.
Overexpression of NF45 led to a modest increase in Luc expression, indicating it enhanced infection
(Figure 2A). NF45 has been shown to interact with the RNA of several viruses [32,33], leading us to
hypothesize that it interacted with HIV RNA. To initially test this hypothesis, we tested if deleting
the RNA binding domain of NF45 would mitigate its ability to enhance HIV infection. A mutant
with a deletion in the N-terminal RGG domain was constructed (∆RGG) and tested in infection
experiments. Deletion of the RGG domain ablated the ability of NF45 to enhance HIV infection
(Figure 2A). To confirm the enhancement effect of NF45 we repeated the infection experiments with
wild-type non-pseudotyped HIV and measured the production of virus from infected cells by reverse
transcription assay (Figure 2B). Similar to the Luc assays, a small, but significant increase in HIV
infection occurred in cells over-expressing NF45.
Next we investigated NF90. Knockdown of NF90 by RNA interference reduces HIV gene
expression and the overexpression of NF90 had already been shown to enhance HIV gene expression
in co-transfection experiments [12,18]. We initially sought to examine the effect of NF90 expression on
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HIV infection. The overexpression of NF90 increased HIV infection in both HIV-Luc infection assays
(Figure 2A) as well as single cycle virus production assays (Figure 2C). Similar to NF45, NF90 has
also been implicated in the replication of several RNA viruses [34,35], and we again hypothesized
that NF90 may be eliciting its effects via RNA binding. Two deletion mutants predicted to disrupt
the RNA binding function of NF90 were created (Figure 1): one contained an in-frame deletion of
the two DRBMs (∆DRBM) and the second was a large C-terminal deletion that deleted both DRBMs
and the RGG motif (∆CT). Although the expression of the mutants was not as robust as wild-type
NF90, neither mutant significantly boosted HIV-Luc infection compared to control transfected cells
(Figure 2A). These data suggested that similar to NF45 the RNA binding function of NF90 was required
for the enhancement of infection.
Notably NF45 binds NF90 via its DZF motif and enhances NF90 activities [36,37]. Since both
NF45 and NF90 enhanced HIV infection, we next tested if overexpression of both factors together
would further enhance infection. To our surprise, robust expression of both proteins did not provide
any substantial boost to infection levels compared to NF45 or NF90 alone (Figure 2A). These data
suggested that the factors may be acting through the same mechanism or pathway that is saturated by
overexpression of either protein.
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Figure 2. NF45 and NF90 potentiate human im unodeficiency virus (HIV) infection. (A) 293T cells
were transfected with the indicated expression vectors or pcDNA3.1 empty vector as a control. After
24 h the cells were infected with vesicular stomatitis virus glycoprotein (VSVg)-pseudotyped HIV-Luc
reporter virus. At 24 h post-infection (hpi), the cells were harvested and infection quantified by Luc
assay and normalized to protein concentration. Results in this, and all other panels are presented
relative to the control group. Error bars in this and all other figures represent standard error of the
mean. Protein expression was monitored by immunoblot using β-actin as a control (bottom panels);
(B,C) Single cycle production assays for NF45 and NF90, respectively. Cells pre-transfected with
plasmids to indicated factors for 24 h ere trans uced with HIV pseudotyped with VSVg After 4 h
the media was changed and the cells incubated an additional 8 h. Cell supe natants were collected
and virus production measured by in vitro reverse transcriptase assay as described i Materials and
Methods. Plots in all panels show the total data from three independent experiments with triplicate
transfections; blots are representative of all three experiments. (* p < 0.05 and ** p < 0.01 by two-tailed
t-test in this and all figures).
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Any change in the level of infection could result from either a boost in the level of the early
steps of virus replication (e.g., entry, reverse transcription, nuclear import, or integration) or higher
gene expression after integration. To test if NF45 was affecting HIV gene expression, we performed
co-transfection experiments with the wild-type and ∆RGG NF45 expression vectors and pNLX-Luc
plasmid. Co-expression of NF45 resulted in a near eight-fold increase in Luc expression, whereas the
∆RGG mutant only slightly increased HIV expression (Figure 3A). The increase in gene expression was
confirmed by measuring virus production from cells co-transfected with NF45 and the full-length pNLX
HIV-1 molecular clone by measuring reverse transcriptase (RT) activity released into cell supernatants.
Co-transfection of NF45 with pNLX resulted in a two-fold increase in virus production compared
to control cells (Figure 3B). Combined, these data indicated that NF45 increases HIV infection by
promoting gene expression and the effect requires the RNA binding domain of NF45.
Next we performed the co-transfection assays with NF90, ∆DRBM and ∆CT. Similar to the
previous observations [18], NF90 significantly increased viral gene expression compared to control
transfected cells as measured by Luc production (Figure 3A) or virus produced from cells (Figure 3C).
However, deletion of the RNA binding domains of NF90, in either the ∆DRBM or ∆CT mutant, ablated
the ability of NF90 to enhance virus production (Figure 3A). Once again, co-transfection of NF45
and NF90 together did not enhance virus expression substantially compared to either factor alone.
Combined these data demonstrate that the ability of both NF45 and NF90 to enhance HIV virus
production requires their RNA binding domains.
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It was reported that the knockdown of NF90 by RNA interference reduces cyclin T1 expression
and decreases HIV gene expression [18]. However, knockdown of NF45 and NF90 has been shown
to retard the cell growth [10], which would reduce viral expression. To revisit this issue, we knocked
down NF45 or NF90 in 293T cells using siRNAs and performed virus infection and production assays
as well as MTT assays to monitor cell viability. As shown in Figure 4A, in our hands virus infection was
modestly, but not substantially reduced by knockdown of either NF45 or NF90. Virus gene expression
was similarly impacted in co-transfection assays (Figure 4B). However, MTT assays revealed that
knockdown of either NF45 or NF90 reduced cell health (Figure 4C), suggesting a mechanism for the
loss of infection or production. Immunoblots confirmed the expected reductions in NF45 and NF90
expression. We also examined the levels of cyclin T1 in the knockdown cells (Figure 4A, blots). Neither
the depletion of NF45, nor, in contrast to previous reports, NF90 substantially changed the levels of
cyclin T1 expression in our experiments.
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Figure 4. Knockdown studies of NF45 and NF90. (A) Cells were pre-transfected with small interfering
RNAs (siRNAs) against NF45, NF90 or with scrambled siRNAs as a control. After 24 h cells were
infected with VSVg-pseudotyped HIV-Luc reporter virus. At 24 hpi, cells were harvested and infection
quantified by Luc assay and normalized to protein concentration. Knockdown was confirmed by
immunoblot using β-actin as a control (panels at right); (B) The effect of knockdown on HIV gene
expression. HIV-Luc plasmid was co-transfected with indicated siRNAs. After 24 h the cells were
harvested and gene expression quantified by the amount of Luc produced relative to total protein
concentration; (C) MTT assays. Cells transfected with siNF45, siNF90 and scramble siRNA as control
were tested for viability by MTT assay after 24 h. Plots show the total data from three independent
experiments with triplicate transfections; blots are representative of all three experiments.
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To further assess if cyclin T1 was contributing to the positive effect of NF45 or NF90 on HIV gene
expression, we tested if cyclin T1 levels were altered in NF45 or NF90 over-expressing cells. To do
this, we transfected increasing amounts of either NF45 or NF90 and examined the expression of cyclin
T1 by immunoblot. As shown in Figure 5, we did not observe a change in the expression of cyclin
T1 upon overexpression NF45 (top panels) or NF90 (bottom panels). Therefore, we concluded that
the enhancement of HIV infection was not due to an increase in the expression of cyclin T1 resulting
in increased promoter activity. We also probed the expression of NF90 upon NF45 overexpression
and NF45 upon NF90 overexpression. Similar to our initial experiments (Figures 2A and 3A), the
overexpression of either factor did not appear to affect the expression of the other.
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Figure 5. Cyclin T1 expression in cells over-expressing NF45 and NF90. 293T cells were transfected with
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of duplicate experiments.
3.2. NF45 and NF90 Interact with HIV RNA
Both NF45 and NF90 are promiscuous RNA binding proteins. NF45 binds single stranded RNA,
whereas NF90 contains two double-stranded RNA binding motifs [37,38]. NF90 has been shown to
hav some binding sel ctivity as it has been shown to selectively repress he translation of RNAs
bearing AU-rich elements [39]. Since th RNA binding domains of both protei s were required for
the enhancement of HIV xp ession, we hypothe ized that both proteins were interacting with the
HIV RNA. To test this e performed IP-RT-PCR ass ys i infected cells. For these experiments, cells
were pre-transfected with FLAG-tagge constructs and infected wit HIV+VSVg for 24 h. The cells
were lysed and immunoprecipitated with anti-FLAG beads. The immunoprecipitates were proteinase
treated, and RNA isolated by acid phenol: chloroform extraction. The capture of HIV RNA was
detected by real-time RT-PCR using gag-specific primers (Figure 6). Numerous controls were used to
confirm the specificity of binding, including non-transfected cells, cells inoculated with heat-inactivated
virus, and immunoprecipitation with an isotype control antibody. The results showed that both NF45
(Figure 6A) and NF90 (Figure 6B) interacted with HIV RNA. As expected, deletion of the RNA binding
domains of either protein resulted in a loss of interaction with HIV RNA.
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NF45 and NF90 have been shown to interact with other RNA binding proteins through binding
to RNA. For example, the interaction of NF90/110 with the RNA-editing factor, adenosine deaminase
acting on RNA (ADAR) is bridged by dsRNAs [40,41]. Another recent proteomic analysis of NF90 and
NF110 binding proteins in mouse brain found that NF90 and NF110 interact with numerous hnRNPs,
including A/B, A2/B1, A3, D, Q, as well as polypyrimidine tract-binding protein-associated-splicing
factor [42]. Therefore it is possible that the NF45 and NF90/110 might interact with HIV RNA indirectly
by binding other RNA binding proteins. To determine if NF45 or NF90 bound directly to HIV RNA,
we performed in vitro cross-linking assays. Recombinant, HIS-tagged NF45 and NF90 were expressed
in E. coli and purified by affinity chromatography (Figure 7A). Since both NF45 and NF90 may enhance
the transcription of the HIV promoter activity, it suggested that the proteins may bind the 51 end of
the HIV RNA. Therefore, the RNA probes were designed to cover the LTR region of HIV-1, including
the R and U5 regions (Figure 7B). We also constructed two probes covering the U3 region of the LTR
which is present only in the 31 end of the HIV mRNA. RNA probes were made by in vitro transcription
and labeled with [32P]-UTP. After incubation at 37 ˝C, protein-radiolabeled RNA complexes were
UV-crosslinked, digested by RNase, separated by SDS-PAGE, and imaged using a phosphorimager.
In all experiments the 31 UTR of the IL-2 mRNA was used as a positive RNA probe control [43], and
purified GST protein was used as a negative input protein control. As seen in Figure 7C, we detected
the interaction of NF45 with RNAs from the U3 and TAR regions of the HIV LTR (arrows), but not
the U5 region. The non-specific bands may represent incompletely digested RNAs or cross-linking to
background proteins in the protein preparations. NF90 cross-linked to RNAs from the 51 half of U3
and the TAR region (Figure 7D), but not the 31 half of U3 or the U5 regions. These results indicate that
NF45 and NF90 bind HIV RNA, but the binding of multiple regions of the RNA suggested that the
interactions were not sequence specific.
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In vitro RNA binding assays with rNF45 (C) and rNF90 (D). Recombinant proteins were incubated
with radiolabeled RNA probes to regions indicated at top (IL2 31 UTR was used as a positive control).
Samples were cross-linked by UV exposure and treated with RNase A prior to separation by SDS-PAGE.
Gels were imaged using a phosphorimager. Arrows indicate expected migration for HIS-tagged NF45
(C) and NF90 (D) proteins.
3.3. NF90 Stabilizes HIV LTR-Containing RNA in Vivo
Protein expression can be affected by many factors including the half-life of the mRNA. NF90
is known to stabilize the interleukin-2 mRNA by binding to the AU-rich element located within IL-2
mRNA 31-UTR [43]. The phosphorylation of NF90 Ser647 is critical for this effect [44]. Since we
observed that NF45 and NF90 bind HIV RNA, we sought to determine if either factor affected the
stability of the RNA. Treatment with the RNA transcription inhibitor actinomycin D (ActD) is a widely
used approach to study RNA decay, but low levels have been shown to upregulate HIV expression due
to hyper-phosphorylation of C-terminal domain of RNA polymerase II [45,46]. Therefore, to measure
HIV RNA decay we constructed a minimal inducible construct containing the HIV TAR and R3
RNA regions under control of tetracycline response element (pTRE-LTR). The construct was stably
transfected into HeLa Tet-On® 3G Cell Line and the expression of the HIV RNA element was induced
by addition of doxycycline (Dox; Figure 8A). Thus, upon removal of Dox RNA transcription ceases
and the decay rate of the RNA could be measured by real-time RT-PCR. To test if NF45 or NF90
impacted RNA stability, we transfected NF45 and NF90 24 h prior to the addition of Dox. After
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12 h of Dox treatment the cells were washed and RNA then harvested at 0, 8, 16, 24 and 32 h post
washout. The level of HIV RNA was measured by real-time PCR and normalized to the level of 18S
ribosomal RNA (Figure 8B). The half-life of LTR RNA in mock-transfected cells was approximately
8 h. The overexpression of NF45 did not alter the decay rate of the RNA, but the overexpression of
NF90 substantially increased the half-life of the RNA to approximately 24 h. These results suggest that
one mechanism by which NF90 increases virus production may be stabilization of the HIV RNA.
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Figure 8. NF90 stabilizes the HIV RNA. (A) Inducible expression of HIV RNA. Transcription of HIV
RNA in doxycycline inducible cell line (B) RNA stability assay. HeLa-HIV RNA cells were transfected
with empty vector, pCMV-NF45 or pEF-NF90. After 24 h doxycycline was added to each well to induce
the expression of HIV RNA. At 12 h post induction the cells were washed three times with warm
cDMEM and returned to normal media to halt transcription. RNA was harvested at the indicated
times and quantified by real-time RT-PCR. Results were normalized to the level of 18S RNA. Error bars
represent standard deviation of triplicate PCR reactions.
4. Discussion
HIV utilizes host factors to facilitate replication and it would be expected that an increased
expression of certain factors might potentiate virus infection. Identifying these factors may point
toward pathways critical for virus replication that can be exploited for inhibitor development.
We identified NF45 and NF90 in a previous proteomic screen [5]. Previous studies demonstrated
that the knockdown of NF90 impaired HIV gene expression [18]; however, it has been shown that
the knockdown of NF90 significantly impacts cell growth [10]. Moreover, NF90 knockout mice
die within 12 h due to neuromuscular respiratory failure [11]. Therefore, it is possible that loss of
cell viability caused the reduction in HIV infection irrespective of protein function. Indeed, in our
experiments, the loss of infection upon knockdown of either NF45 or NF90 correlated with a loss
of cell viability. Therefore the major focus of these studies was to examine the effects of positive
expression of these proteins. We found that NF45 and NF90 potentiated HIV infection by promoting
HIV gene expression. Notably, neither overexpression nor knockdown of NF45 or NF90 appeared
to affect cyclin T1 expression in our studies, although further quantitative studies are necessary to
definitively address this issue. The RNA binding domains of both proteins were required to potentiate
HIV expression. Both NF45 and NF90 were found to bind HIV RNA in vitro, but the interactions
appeared to be non-specific. Finally, overexpression of NF90, but not NF45, slowed the decay of an
RNA containing HIV LTR elements. Combined these data indicate that both NF45 and NF90 are
positive regulators of HIV transcription. NF90 may also upregulate HIV gene expression by stabilizing
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the HIV RNA. The role of NF45 RNA binding remains unclear. Interestingly, overexpression of both
proteins did not have an additive effect on HIV gene expression. This suggests both proteins may
act independently in the same pathway. Alternatively, the addition of one or the other factor may be
sufficient to saturate effector sites on the HIV RNA or interactions with cellular factors that stimulate
HIV gene expression [37]. Further studies with mutants known to disrupt the NF45-NF90 interface
would clarify this issue [9,37].
The pleiotropic effects of NF45 and NF90 on HIV expression were not surprising as these
are multifunction nuclear proteins that regulate cellular gene expression at different levels [47–49].
These functions include DNA damage repair mediated by DNA-PK [7], RNA translation [39,50] and
microRNA biogenesis [51,52]. Indeed, NF45 and NF90 have been shown to alter the replication cycles
of a number of viruses. NF90 interacts with the 51 end of the hepatitis C virus RNA and is necessary
for efficient virus replication [53]. NF90 binds the 31 end of dengue virus RNA and potentiates virus
replication [35]. The overexpression of NF90 inhibits influenza virus replication during the early phase
of infection through an interaction with the viral nucleoprotein [34]. NF45 accumulates at sites of
replication of infectious bursa disease virus (IBDV) and it may negatively regulate IBDV replication as
siRNA knockdown of NF45 enhances replication [33]. It has also been found that knockdown of NF45
or NF90 restores the expression of the p53 and p21 proteins in cervical carcinoma cells infected with
high-risk human papillomaviruses (HPVs) [47]. It has also been shown that NF90 is a component of
stress granules, which possess antiviral activity [54].
While our data suggest that NF45 and NF90 increase HIV production through interactions with
HIV RNA, we cannot exclude the possibility that they may control the expression of other host factors
and lead to an enhancement of infection. Proteomic analyses of the NF90/110 interactome show
interactions with a number of RNA processing proteins, including numerous Heterogeneous nuclear
ribonucleoproteins (hnRNPs) [42]. NF90 has also been shown to interact with the anti-viral factor
PKR, which is known to be inhibited during HIV infection [55,56]. It could be possible that the
overexpression of NF90 alters PKR activity in a manner that enhances HIV infection. The transcription
factor YY1 is another HIV factor that interacts with NF90 [57,58]. YY1 has been shown to repress
LTR activity; therefore, NF90 overexpression may sequester this factor and lead to increased viral
gene expression. Further studies that compare the interactomes of NF45 and NF90 in uninfected
and HIV infected cells are needed to address this issue and identify other factors that may alter HIV
gene expression.
The NF90ctv C-terminal variant of NF90 was shown to reduce HIV gene expression by competing
with Tat for binding to TAR RNA [19]. Our data confirmed that NF90 binds TAR, but show clearly
that overexpression of NF90 potentiates HIV gene expression. Combined with previous data [18], we
believe these results convincing show that NF90 is a positive regulator HIV infection. It may be that the
alteration in the C-terminus of NF90ctv may create a dominant negative mutant of HIV transcription.
Lastly, in contrast to Hoque et al. we found that NF45 potentiates HIV transcription and infection
using two independent experimental systems. This discrepancy may be due to the variability in
methodology including the cell lines (HeLa vs. 293T), strains of virus used, or the nature of the NF45
expression vectors used. NF45 has been shown to interact with the RNA of several viruses. In addition
to IBDV, NF45 was found to bind the IRES of rhinovirus type 2 and inhibit translation [59]. It has also
been shown to interact with the hepatitis C capsid protein via a RNA intermediate [60], although the
functional consequence of this interaction is unknown. We show that NF45 enhances HIV infection
by upregulating HIV gene expression, and we observed that it bound HIV RNA but did not alter
its stability. We do not yet know how NF45 increases HIV infection. It may potentiate translation,
or activate gene expression through a cellular pathway. Further studies will be needed to delineate the
role of NF45 in HIV replication.
Acknowledgments: This work was supported by Public Health Service grant AI080348 from the National Institute
of Allergy and Infectious Diseases. The following reagent was obtained through the NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH: pSV2tat72 from Alan Frankel.
Viruses 2016, 8, 47 14 of 17
Author Contributions: Yan Li and Michael Belshan conceived and designed the experiments and wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Frankel, A.D.; Young, J.A.T. HIV-1: Fifteen proteins and an RNA. Annu. Rev. Biochem. 1998, 67, 1–25.
[CrossRef] [PubMed]
2. Ako-Adjei, D.; Fu, W.; Wallin, C.; Katz, K.S.; Song, G.; Darji, D.; Brister, J.R.; Ptak, R.G.; Pruitt, K.D. HIV-1,
human interaction database: Current status and new features. Nucleic Acids Res. 2014, 43, D566–D570.
[CrossRef] [PubMed]
3. Fatkenheuer, G.; Pozniak, A.L.; Johnson, M.A.; Plettenberg, A.; Staszewski, S.; Hoepelman, A.I.M.; Saag, M.S.;
Goebel, F.D.; Rockstroh, J.K.; Dezube, B.J.; et al. Efficacy of short-term monotherapy with maraviroc, a new
CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 2005, 11, 1170–1172. [CrossRef] [PubMed]
4. DeBoer, J.; Jagadish, T.; Haverland, N.A.; Madson, C.J.; Ciborowski, P.; Belshan, M. Alterations in the nuclear
proteome of HIV-1 infected T-cells. Virology 2014, 468–470, 409–420. [CrossRef] [PubMed]
5. Schweitzer, C.J.; Jagadish, T.; Haverland, N.; Ciborowski, P.; Belshan, M. Proteomic analysis of early HIV-1
nucleoprotein complexes. J. Proteome Res. 2013, 12, 559–572. [CrossRef] [PubMed]
6. Li, Y.; Frederick, K.M.; Haverland, N.A.; Ciborowski, P.; Belshan, M. Investigation of the HIV-1 matrix
interactome during virus replication. Proteomics Clin. Appl. 2015, 10, 156–163. [CrossRef] [PubMed]
7. Shamanna, R.A.; Hoque, M.; Lewis-Antes, A.; Azzam, E.I.; Lagunoff, D.; Pe’ery, T.; Mathews, M.B.
The NF90/NF45 complex participates in DNA break repair via nonhomologous end joining. Mol. Cell. Biol.
2011, 31, 4832–4843. [CrossRef] [PubMed]
8. Kiesler, P.; Haynes, P.A.; Shi, L.; Kao, P.N.; Wysocki, V.H.; Vercelli, D. NF45 and NF90 regulate HS4-dependent
interleukin-13 transcription in T cells. J. Biol. Chem. 2010, 285, 8256–8267. [CrossRef] [PubMed]
9. Wandrey, F.; Montellese, C.; Koos, K.; Badertscher, L.; Bammert, L.; Cook, A.G.; Zemp, I.; Horvath, P.; Kutay, U.
The NF45/NF90 heterodimer contributes to the biogenesis of 60S ribosomal subunits and influences nucleolar
morphology. Mol. Cell. Biol. 2015, 35, 3491–3503. [CrossRef] [PubMed]
10. Guan, D.; Altan-Bonnet, N.; Parrott, A.M.; Arrigo, C.J.; Li, Q.; Khaleduzzaman, M.; Li, H.; Lee, C.G.; Pe’ery, T.;
Mathews, M.B. Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in
mitotic control. Mol. Cell. Biol. 2008, 28, 4629–4641. [CrossRef] [PubMed]
11. Shi, L.; Zhao, G.; Qiu, D.; Godfrey, W.R.; Vogel, H.; Rando, T.A.; Hu, H.; Kao, P.N. NF90 regulates cell cycle
exit and terminal myogenic differentiation by direct binding to the 31-untranslated region of MyoD and
p21WAF1/CIP1 mRNAs. J. Biol. Chem. 2005, 280, 18981–18989. [CrossRef] [PubMed]
12. Reichman, T.W.; Mathews, M.B. RNA binding and intramolecular interactions modulate the regulation of
gene expression by nuclear factor 110. RNA 2003, 9, 543–554. [CrossRef] [PubMed]
13. Reichman, T.W.; Parrott, A.M.; Fierro-Monti, I.; Caron, D.J.; Kao, P.N.; Lee, C.-G.; Li, H.; Mathews, M.B.
Selective regulation of gene expression by nuclear factor 110, a member of the NF90 family of double-stranded
RNA-binding proteins. J. Mol. Biol. 2003, 332, 85–98. [CrossRef]
14. Kinoshita, S.; Su, L.; Amano, M.; Timmerman, L.A.; Kaneshima, H.; Nolan, G.P. The T cell activation factor
NF-ATC positively regulates HIV-1 replication and gene expression in T cells. Immunity 1997, 6, 235–244.
[CrossRef]
15. Parada, C.A.; Roeder, R.G. Enhanced processivity of RNA polymerase II triggered by Tat-induced
phosphorylation of its carboxy-terminal domain. Nature 1996, 384, 375–378. [CrossRef] [PubMed]
16. Fields, B.N.; Knipe, D.M.; Howley, P.M. Fields Virology, 5th ed.; Wolters Kluwer Health/Lippincott Williams
& Wilkins: Philadelphia, PA, USA, 2007.
17. Yang, X.; Gold, M.O.; Tang, D.N.; Lewis, D.E.; Aguilar-Cordova, E.; Rice, A.P.; Herrmann, C.H. Tak, an
HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by
activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc. Natl Acad.
Sci. USA 1997, 94, 12331–12336. [CrossRef] [PubMed]
18. Hoque, M.; Shamanna, R.A.; Guan, D.; Pe’ery, T.; Mathews, M.B. HIV-1 replication and latency are regulated
by translational control of cyclin T1. J. Mol. Biol. 2011, 410, 917–932. [CrossRef] [PubMed]
19. Agbottah, E.T.; Traviss, C.; McArdle, J.; Karki, S.; St Laurent, G.C., 3rd; Kumar, A. Nuclear factor 90 (NF90)
targeted to Tar RNA inhibits transcriptional activation of HIV-1. Retrovirology 2007, 4. [CrossRef] [PubMed]
Viruses 2016, 8, 47 15 of 17
20. Urcuqui-Inchima, S.; Castano, M.E.; Hernandez-Verdun, D.; St-Laurent, G., 3rd; Kumar, A. Nuclear factor 90,
a cellular dsRNA binding protein inhibits the HIV rev-export function. Retrovirology 2006, 3. [CrossRef]
[PubMed]
21. Urcuqui-Inchima, S.; Patino, C.; Zapata, X.; Garcia, M.P.; Arteaga, J.; Chamot, C.; Kumar, A.;
Hernandez-Verdun, D. Production of HIV particles is regulated by altering sub-cellular localization and
dynamics of rev induced by double-strand RNA binding protein. PLoS ONE 2011, 6, e16686. [CrossRef]
[PubMed]
22. Krasnoselskaya-Riz, I.; Spruill, A.; Chen, Y.W.; Schuster, D.; Teslovich, T.; Baker, C.; Kumar, A.; Stephan, D.A.
Nuclear factor 90 mediates activation of the cellular antiviral expression cascade. AIDS Res. Hum. Retroviruses
2002, 18, 591–604. [CrossRef] [PubMed]
23. Brown, H.E.; Chen, H.; Engelman, A. Structure-based mutagenesis of the human immunodeficiency virus
type 1 DNA attachment site: Effects on integration and cDNA synthesis. J. Virol. 1999, 73, 9011–9020.
[PubMed]
24. Connor, R.I.; Chen, B.K.; Choe, S.; Landau, N.R. VPR is required for efficient replication of human
immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206, 935–944. [CrossRef]
[PubMed]
25. He, J.; Choe, S.; Walker, R.; Di Marzio, P.; Morgan, D.O.; Landau, N.R. Human immunodeficiency virus type
1 viral protein r (VPR) arrests cells in the G2 phase of the cell cycle by inhibiting P34CDC2 activity. J. Virol.
1995, 69, 6705–6711. [PubMed]
26. Frankel, A.D.; Pabo, C.O. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988,
55, 1189–1193. [CrossRef]
27. Jeeninga, R.E.; Hoogenkamp, M.; Armand-Ugon, M.; de Baar, M.; Verhoef, K.; Berkhout, B. Functional
differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus
type 1 subtypes A through G. J. Virol. 2000, 74, 3740–3751. [CrossRef] [PubMed]
28. Klaver, B.; Berkhout, B. Comparison of 51 and 31 long terminal repeat promoter function in human
immunodeficiency virus. J. Virol. 1994, 68, 3830–3840. [PubMed]
29. Sanford, B.; Li, Y.; Maly, C.J.; Madson, C.J.; Chen, H.; Zhou, Y.; Belshan, M. Deletions in the fifth alpha helix
of HIV-1 matrix block virus release. Virology 2014, 468, 293–302. [CrossRef] [PubMed]
30. Belshan, M.; Schweitzer, C.J.; Donnellan, M.R.; Lu, R.; Engelman, A. In vivo biotinylation and capture of
HIV-1 matrix and integrase proteins. J. Virol. Methods 2009, 159, 178–184. [CrossRef] [PubMed]
31. Schweitzer, C.J.; Matthews, J.M.; Madson, C.J.; Donnellan, M.R.; Cerny, R.L.; Belshan, M. Knockdown of the
cellular protein LRPPRC attenuates HIV-1 infection. PLoS ONE 2012, 7, e40537. [CrossRef] [PubMed]
32. Isken, O.; Baroth, M.; Grassmann, C.W.; Weinlich, S.; Ostareck, D.H.; Ostareck-Lederer, A.; Behrens, S.-E.
Nuclear factors are involved in hepatitis C virus RNA replication. RNA 2007, 13, 1675–1692. [CrossRef]
[PubMed]
33. Stricker, R.L.; Behrens, S.E.; Mundt, E. Nuclear factor NF45 interacts with viral proteins of infectious bursal
disease virus and inhibits viral replication. J. Virol. 2010, 84, 10592–10605. [CrossRef] [PubMed]
34. Wang, P.; Song, W.; Mok, B.W.; Zhao, P.; Qin, K.; Lai, A.; Smith, G.J.; Zhang, J.; Lin, T.; Guan, Y.; et al. Nuclear
factor 90 negatively regulates influenza virus replication by interacting with viral nucleoprotein. J. Virol.
2009, 83, 7850–7861. [CrossRef] [PubMed]
35. Gomila, R.C.; Martin, G.W.; Gehrke, L. NF90 binds the dengue virus RNA 31 terminus and is a positive
regulator of dengue virus replication. PLoS ONE 2011, 6, e16687. [CrossRef] [PubMed]
36. Reichman, T.W.; Muniz, L.C.; Mathews, M.B. The RNA binding protein nuclear factor 90 functions as both a
positive and negative regulator of gene expression in mammalian cells. Mol. Cell. Biol. 2002, 22, 343–356.
[CrossRef] [PubMed]
37. Wolkowicz, U.M.; Cook, A.G. NF45 dimerizes with NF90, ZFR and SPNR via a conserved domain that has a
nucleotidyltransferase fold. Nucleic Acids Res. 2012, 40, 9356–9368. [CrossRef] [PubMed]
38. Faye, M.D.; Graber, T.E.; Liu, P.; Thakor, N.; Baird, S.D.; Durie, D.; Holcik, M. Nucleotide composition of
cellular internal ribosome entry sites defines dependence on NF45 and predicts a posttranscriptional mitotic
regulon. Mol. Cell. Biol. 2013, 33, 307–318. [CrossRef] [PubMed]
39. Kuwano, Y.; Pullmann, R., Jr.; Marasa, B.S.; Abdelmohsen, K.; Lee, E.K.; Yang, X.; Martindale, J.L.; Zhan, M.;
Gorospe, M. NF90 selectively represses the translation of target mRNAs bearing an AU-rich signature motif.
Nucleic Acids Res. 2010, 38, 225–238. [CrossRef] [PubMed]
Viruses 2016, 8, 47 16 of 17
40. Nie, Y.Z.; Ding, L.; Kao, P.N.; Braun, R.; Yang, J.H. ADAR1 interacts with NF90 through double-stranded
RNA and regulates NF90-mediated gene expression independently of RNA editing. Mol. Cell. Biol. 2005, 25,
6956–6963. [CrossRef] [PubMed]
41. Doria, M.; Neri, F.; Gallo, A.; Farace, M.G.; Michienzi, A. Editing of HIV-1 RNA by the double-stranded RNA
deaminase ADAR1 stimulates viral infection. Nucleic Acids Res. 2009, 37, 5848–5858. [CrossRef] [PubMed]
42. Chaumet, A.; Castella, S.; Gasmi, L.; Fradin, A.; Clodic, G.; Bolbach, G.; Poulhe, R.; Denoulet, P.; Larcher, J.C.
Proteomic analysis of interleukin enhancer binding factor 3 (ilf3) and nuclear factor 90 (NF90) interactome.
Biochimie 2013, 95, 1146–1157. [CrossRef] [PubMed]
43. Shim, J.; Lim, H.; Yates, J.R.; Karin, M. Nuclear export of NF90 is required for interleukin-2 mRNA
stabilization. Mol. Cell. 2002, 10, 1331–1344. [CrossRef]
44. Pei, Y.; Zhu, P.; Dang, Y.; Wu, J.; Yang, X.; Wan, B.; Liu, J.O.; Yi, Q.; Yu, L. Nuclear export of NF90 to stabilize
IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation.
J. Immunol. 2008, 180, 222–229. [CrossRef] [PubMed]
45. Casse, C.; Giannoni, F.; Nguyen, V.T.; Dubois, M.F.; Bensaude, O. The transcriptional inhibitors, actinomycin
D and α-amanitin, activate the HIV-1 promoter and favor phosphorylation of the RNA polymerase II
C-terminal domain. J. Biol. Chem. 1999, 274, 16097–16106. [CrossRef] [PubMed]
46. Imamichi, T.; Murphy, M.A.; Adelsberger, J.W.; Yang, J.; Watkins, C.M.; Berg, S.C.; Baseler, M.W.;
Lempicki, R.A.; Guo, J.; Levin, J.G.; et al. Actinomycin D induces high-level resistance to thymidine
analogs in replication of human immunodeficiency virus type 1 by interfering with host cell thymidine
kinase expression. J. Virol. 2003, 77, 1011–1020. [CrossRef] [PubMed]
47. Shamanna, R.A.; Hoque, M.; Pe’ery, T.; Mathews, M.B. Induction of p53, p21 and apoptosis by silencing the
NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells. Oncogene 2013, 32,
5176–5185. [CrossRef] [PubMed]
48. Patino, C.; Haenni, A.L.; Urcuqui-Inchima, S. NF90 isoforms, a new family of cellular proteins involved in
viral replication? Biochimie 2014, 108, 20–24. [CrossRef] [PubMed]
49. Castella, S.; Bernard, R.; Corno, M.; Fradin, A.; Larcher, J.C. ILF3 and NF90 functions in RNA biology.
Wiley Interdiscip. Rev. RNA 2015, 6, 243–256. [CrossRef] [PubMed]
50. Neplioueva, V.; Dobrikova, E.Y.; Mukherjee, N.; Keene, J.D.; Gromeier, M. Tissue type-specific expression of
the dsRNA-binding protein 76 and genome-wide elucidation of its target mRNAs. PLoS ONE 2010, 5, e11710.
[CrossRef] [PubMed]
51. Masuda, K.; Kuwano, Y.; Nishida, K.; Rokutan, K.; Imoto, I. NF90 in posttranscriptional gene regulation and
microRNA biogenesis. Int. J. Mol. Sci. 2013, 14, 17111–17121. [CrossRef] [PubMed]
52. Sakamoto, S.; Aoki, K.; Higuchi, T.; Todaka, H.; Morisawa, K.; Tamaki, N.; Hatano, E.; Fukushima, A.;
Taniguchi, T.; Agata, Y. The NF90-NF45 complex functions as a negative regulator in the microRNA
processing pathway. Mol. Cell. Biol. 2009, 29, 3754–3769. [CrossRef] [PubMed]
53. Li, Y.; Masaki, T.; Shimakami, T.; Lemon, S.M. HNRNP L and NF90 interact with hepatitis C virus 51-terminal
untranslated RNA and promote efficient replication. J. Virol. 2014, 88, 7199–7209. [CrossRef] [PubMed]
54. Wen, X.; Huang, X.; Mok, B.W.; Chen, Y.; Zheng, M.; Lau, S.Y.; Wang, P.; Song, W.; Jin, D.Y.; Yuen, K.Y.; et al.
NF90 exerts antiviral activity through regulation of PKR phosphorylation and stress granules in infected
cells. J. Immunol. 2014, 192, 3753–3764. [CrossRef] [PubMed]
55. Patel, R.C.; Vestal, D.J.; Xu, Z.; Bandyopadhyay, S.; Guo, W.; Erme, S.M.; Williams, B.R.; Sen, G.C. DRBP76,
a double-stranded RNA-binding nuclear protein, is phosphorylated by the interferon-induced protein kinase,
PKR. J. Biol. Chem. 1999, 274, 20432–20437. [CrossRef] [PubMed]
56. Clerzius, G.; Gelinas, J.F.; Gatignol, A. Multiple levels of PKR inhibition during HIV-1 replication.
Rev. Med. Virol. 2011, 21, 42–53. [CrossRef] [PubMed]
57. Rezai-Zadeh, N.; Zhang, X.; Namour, F.; Fejer, G.; Wen, Y.D.; Yao, Y.L.; Gyory, I.; Wright, K.; Seto, E. Targeted
recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes Dev. 2003, 17,
1019–1029. [CrossRef] [PubMed]
58. Coull, J.J.; Romerio, F.; Sun, J.M.; Volker, J.L.; Galvin, K.M.; Davie, J.R.; Shi, Y.; Hansen, U.; Margolis, D.M.
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via
recruitment of histone deacetylase 1. J. Virol. 2000, 74, 6790–6799. [CrossRef] [PubMed]
Viruses 2016, 8, 47 17 of 17
59. Merrill, M.K.; Gromeier, M. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits
translation initiation at the rhinovirus type 2 internal ribosome entry site. J. Virol. 2006, 80, 6936–6942.
[CrossRef] [PubMed]
60. Lee, J.-W.; Liao, P.-C.; Young, K.-C.; Chang, C.L.; Chen, S.S.L.; Chang, T.-T.; Lai, M.-D.; Wang, S.-W.
Identification of hnRNPH1, NF45, and C14orf166 as novel host interacting partners of the mature hepatitis C
virus core protein. J. Proteome Res. 2011, 10, 4522–4534. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons by Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
